Workflow
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
OPTNOptiNose(OPTN) Newsfilter·2025-01-15 12:00

Core Insights - Optinose reported preliminary unaudited net product revenue of 22.4millionforXHANCEforthefourthquarterof2024,aligningwithpriorguidanceandindicatingsustainedgrowthinprescriptions[1][2]−Thecompanyestimatesasequentialgrowthrateofapproximately2022.4 million for XHANCE for the fourth quarter of 2024, aligning with prior guidance and indicating sustained growth in prescriptions [1][2] - The company estimates a sequential growth rate of approximately 20% in XHANCE prescriptions from the third quarter to the fourth quarter of 2024, reflecting effective commercial execution [2] Financial Performance - The preliminary unaudited net product revenue of 22.4 million for the three months ended December 31, 2024, is based on available information and may vary upon finalization [2] - Full financial results for the fourth quarter of 2024 are expected to be reported in March 2025 [2] Company Overview - Optinose is a specialty pharmaceutical company focused on patients treated by ear, nose, and throat (ENT) and allergy specialists [3]